BEIJING, June 9 /PRNewswire-Asia/ -- RainEarth Inc. (OTC Bulletin Board: RNER; "the Company"), announced today that its contractual partner in China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"), has submitted a patent application for its second generation of blood dialysis.
This second generation blood dialysis has several new features and advantages. These include: a lower broken membrane rate, a higher gap rate, enhanced biological compatibility for the hollow fiber membrane, and an increased dialysis rate.
China RainEarth has applied for patents in a variety of areas with the State Intellectual Property Office of P.R.C (SIPO) including:
-- Scale manufacture method for hollow fiber membranes -- Quick drying equipment for hollow fiber membranes -- Device for adjusting dry spinning range in hollow fiber membrane that includes dry-wet spinning and control condensation bath process concentration control -- Synthetic hollow fiber membrane continuous spinning device -- Hollow fiber membrane porous spinneret component -- Hollow fiber tube-in-orifice spinneret
In May 2009, the China State Council passed new regulations not only to speed up the development of the biological industry in China but also to enhance bio-tech patent protection. Products with intellectual rights, once reviewed and approved, will be included in the national Medical Plan catalog.
"We continuously improve our products and protect our intellectual property by applying for patents. These advantages give China RainEarth a strong position in hollow fiber membrane manufacturing and related fields, solidifies our leadership position and ensures that we stay ahead of our competition", said Mr. Zhu, CEO of the Company.
About the Company
RainEarth Inc. (formerly Gold Rock Resources Inc., the "Company") was incorporated in the State of Nevada on March 14, 2006. The Company is a developing stage company that initially engages in the search for mineral deposits or reserves.
On March 25, 2009, the Company and China RainEarth, a company organized and existing under the laws of the People's Republic of China, entered into a Business Cooperation Agreement (the "Agreement") for a term of twenty years. The purpose of the Agreement is to jointly conduct Hollow Fiber Mambrane Materials' application and manufacturing business in China (the "Business"). The first product that utilizes this technology is blood dialyzer.
The Company will provide Advice and assistance relating to development of marketing and consultancy services, particularly as related to the Business. China RainEarth will give 60% of its revenue after deduction of direct operating costs, expenses and taxes to the Company in consideration of the Company's services.
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion. The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.
For more information, please contact: RainEarth Inc. Public Relationship Department Tel: +852-3005-7220
|SOURCE RainEarth Inc.|
Copyright©2009 PR Newswire.
All rights reserved